Immutep (ASX:IMM) has announced that the open-label safety lead-in of its integrated AIPAC-003 Phase 2/3 trial evaluating 90mg of eftilagimod alpha (efti) in combination with paclitaxel has been completed with no safety or tolerability issues.
Immutep announces the completion of key stage of AIPAC-003 trial in metastatic breast cancer
November 6, 2023 Australian Biotech
Latest Video
New Stories
-
Outcomes published from meeting the PBAC was directed to hold
June 22, 2025 - - Latest News -
TGA-licensed compounders call for review to ensure sustainability
June 20, 2025 - - Latest News -
GLP-1 pill study marks potential new chapter in treating diabetes and weight loss
June 20, 2025 - - Latest News -
An ideological darkness underpins our system's decision-making
June 20, 2025 - - Latest News -
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma